Royalty Pharma Plc

( )
RPRX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
PFEPfizer Inc. 0.18%38.520.9%$1236.32m
JNJJohnson & Johnson 0.41%149.240.7%$878.55m
MRKMerck & Co., Inc. 0.27%81.230.7%$636.24m
BMYBristol-Myers Squibb Co. 1.61%61.991.0%$606.80m
ABBVAbbVie, Inc. 0.10%93.031.9%$598.41m
AZNAstraZeneca Plc 0.54%55.701.2%$567.46m
LLYEli Lilly & Co. 0.06%152.971.1%$430.35m
NVSNovartis AG -0.59%82.450.2%$139.61m
GSKGlaxoSmithKline Plc 0.06%40.820.2%$136.97m
MISTMilestone Pharmaceuticals, Inc. 1.02%9.900.0%$135.31m
OPKOPKO Health, Inc. 0.89%5.6811.2%$133.35m
RGENRepligen Corp. -1.23%152.777.2%$68.82m
NVONovo Nordisk A/S -0.67%64.210.1%$68.41m
PRNBPrincipia Biopharma, Inc. 5.33%91.890.0%$63.33m
SNYSanofi -0.52%51.240.2%$55.30m

Company Profile

Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.